GT Biopharma Announces Dosing First Patient In GTB-3550 TriKE(TM) Phase I/II Clinical Trial February 26, 2020
GT Biopharma Provides Update Concerning Trike(TM) Drug Development Programs and Other Strategic Initiatives January 21, 2020
GT Biopharma Announces Solid Tumor Targeting TriKe™ Kills Non-small Cell Lung Cancer (NSCLC) Tumor Cells October 22, 2019
GT Biopharma Announces HIV TriKE™ Data Demonstrating NK Cell Killing of Patient HIV Infected Cells October 3, 2019
GT Biopharma Announces the Sale of Its Fixed Dose Combination Tablet (GTB-004) for Myasthenia Gravis (Chronic Autoimmune Disease) to DAS Therapeutics September 24, 2019
GT Biopharma Announces FDA Notification of Commencement of Enrollment in Human GTB-3550 Trike™ Phase i/ii Clinical Trial September 12, 2019
